Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights rapid progress in perioperative neuroprotection and trial infrastructure, precision sedation pharmacology, and evidence synthesis guiding anesthetic choice. A placebo-controlled RCT found gastrodin halved postoperative delirium after CABG, modeling/PKPD work quantified remimazolam–remifentanil interactions to support target-controlled dosing, and a large meta-analysis clarified trade-offs between TIVA and inhalational anesthesia for recovery and P
Summary
This week’s anesthesiology literature highlights rapid progress in perioperative neuroprotection and trial infrastructure, precision sedation pharmacology, and evidence synthesis guiding anesthetic choice. A placebo-controlled RCT found gastrodin halved postoperative delirium after CABG, modeling/PKPD work quantified remimazolam–remifentanil interactions to support target-controlled dosing, and a large meta-analysis clarified trade-offs between TIVA and inhalational anesthesia for recovery and PONV. Together these studies push toward mechanistic, patient-centered, and implementable changes in perioperative practice.
Selected Articles
1. Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac surgery: a randomized placebo controlled clinical trial.
Double-blind RCT in 155 CABG (± valve) patients found gastrodin infusion (600 mg twice daily to POD6) reduced postoperative delirium incidence from 35.9% to 19.5% (RR 0.54, p=0.022) and increased odds of hospital discharge, with no drug-related adverse events reported. POCD rates were low and similar between groups.
Impact: First high-quality blinded RCT demonstrating a pharmacologic intervention that significantly reduces delirium after cardiac surgery — a major, common complication with limited preventive options.
Clinical Implications: If replicated, gastrodin could be integrated into multimodal delirium prevention bundles for cardiac surgery patients, with protocolized dosing through POD6 and routine monitoring for efficacy and safety.
Key Findings
- Gastrodin reduced postoperative delirium incidence from 35.9% to 19.5% (RR 0.54; 95% CI 0.32–0.93; p=0.022).
- Greater odds of hospital discharge in gastrodin group (subhazard ratio 1.20; 95% CI 1.00–1.84; p=0.049).
- No drug-related adverse events reported; overall adverse event rates similar between groups.
2. Influence of Remifentanil on the Pharmacokinetics and Pharmacodynamics of Remimazolam in Healthy Volunteers.
A three-period randomized crossover PK/PD study in 24 healthy volunteers quantified a pharmacokinetic interaction (reduced apparent clearance of remimazolam metabolite CNS7054) and pharmacodynamic synergism between remifentanil and remimazolam across MOAAS and BIS. Modeling suggests remimazolam targets of ~200–275 ng/mL combined with remifentanil 0–0.5 ng/mL maximize moderate sedation (MOAAS 2–3) probabilities.
Impact: Provides actionable, quantitative PK/PD data to guide target-controlled remimazolam dosing when used with remifentanil — important for precision sedation and safety (respiratory/cognitive) in perioperative and ICU settings.
Clinical Implications: Clinicians should lower remimazolam targets when co-administering remifentanil and adjust TCI settings and MOAAS/BIS monitoring accordingly to avoid oversedation; the data support integration into closed-loop or protocolized sedation strategies after validation in patients.
Key Findings
- Remifentanil reduced apparent clearance of remimazolam metabolite CNS7054 (half-max inhibition ~8.0 ng/mL).
- Pharmacodynamic interaction across MOAAS, BIS, and stimulation tolerance endpoints was demonstrated.
- Simulations identify remimazolam ~200–275 ng/mL with remifentanil 0–0.5 ng/mL as target combinations to maximize moderate sedation probability (~44–45%).
3. Safety and recovery profile of patients after inhalational anaesthesia versus target-controlled or manual total intravenous anaesthesia: a systematic review and meta-analysis of randomised controlled trials.
Comprehensive meta-analysis of 385 RCTs found no difference in serious intraoperative adverse events between TIVA and inhalational anesthesia. TIVA reduced PONV and emergence agitation, while inhalational anesthesia favored faster recovery times and lower costs; subgroup analyses found similar safety for TCI and manual TIVA but suggested TCI may reduce postoperative cognitive dysfunction while prolonging recovery.
Impact: Largest synthesis to date clarifying trade-offs between anesthetic techniques across key patient-centered and operational outcomes — informs individualized anesthetic selection and policy (environmental/cost) decisions.
Clinical Implications: Choose inhalational anesthesia when rapid recovery and cost are priorities; favor TIVA for patients at high risk of PONV or emergence agitation. Consider TCI-specific studies for cognitive outcomes before changing practice solely on that basis.
Key Findings
- No difference in ClassIntra grade 3–4 adverse events between TIVA and inhalational anesthesia (RR 1.00).
- TIVA associated with lower PONV and emergence agitation; inhalational anesthesia associated with shorter recovery times and lower costs.
- Subgroup analysis: TCI and manual TIVA showed similar safety; TCI may reduce postoperative cognitive dysfunction but could prolong recovery — requires head‑to‑head trials.